Acellbia® and Mabtera® are recognize CD20-positive cells with equal efficiency

In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the sa...

Full description

Saved in:

Bibliographic Details
Published in:	Onkogematologii͡a Vol. 10; no. 4; pp. 56 - 59
Main Authors:	Misyurin, V. A., Misyurin, A. V., Misyurina, A. E., Finashutina, Yu. P., Baryshnikovа, M. A., Burova, O. S., Kravchenko, S. K.
Format:	Journal Article
Language:	English Russian
Published:	ABV-press 23-12-2015
Subjects:	acellbia laboratory diagnostics mabthera monoclonal antibodie sensitivity
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In present study were compared characteristics of rituximab produced by Hoffmann–La Roche (Mabtera®) and first domestic biosimilar Acellbia® from Biocad Company. Concentration of protein was measured using Bradford, s method. According to our results, protein concentration in formulations was the same. We electrophoresed formulations in denaturing conditions. Protein from formulations was denatured into fragments. Heavy and light chains of immunoglobulin were observed in gel. Finally, we performed flow cytometry where rituximab was used as primary antibody to detect CD20-positive B-cells of patients with B-cell chronic lymphocytic leukemia. Both Mabtera® and Acellbia® recognized the same number of cells. Thus, assays performed in vitro submitted identity of Mabtera® and Acellbia® characteristics.
ISSN:	1818-8346 2413-4023
DOI:	10.17650/1818-8346-2015-10-4-56-59